Toxicity Increases With Combined Chemo/Radiation Treatments for Nasopharyngeal Carcinoma
Friday, July 16, 2010
Although the standard practice of treating patients with advanced Nasopharyngeal Carcinoma using radiation and chemotherapy may reduce cancer deaths compared to patients treated with radiation alone, non-cancer related deaths and toxicity problems have been shown to increase, according to a recent study published online in The Journal of the National Cancer Institute....
ScienceDaily (May 30, 2010) — Scientists from Singapore, China and USA have identified three new susceptibility genes in a genome-wide association study of nasopharyngeal carcinoma (NPC). The study, led by the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, identified genetic risk factors of NPC that advance the understanding of the important role played by host genetic...
NEW YORK (Reuters Health) - You've heard about using marijuana and drugs derived from it to keep some of the side effects of toxic cancer chemotherapy in check. But what if smoking marijuana for 10 to 20 years could actually protect against certain tumors?
In a study, researchers have found that long-term pot smokers were roughly 62 percent less likely to develop head and neck cancers than people who did not smoke pot.
By Kristina Fiore, Staff Writer, MedPage Today
Published: July 29, 2009
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
LITTLE FALLS, N.J., July 29 -- Smokeless tobacco does not increase the user's risk of cancers other than oropharyngeal and prostate cancer, according to an industry-sponsored review of data from 89 studies.
New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study
Responses Observed at Lower Doses -- “Flat Dosing” Feasible
June 01, 2009 08:05 AM Eastern Daylight Time
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA.OB) announced preliminary results from its ongoing clinical study of tesetaxel, a leading oral taxane in the Company’s investigational drug portfolio. The new...
